Skip to main content
. Author manuscript; available in PMC: 2011 Dec 15.
Published in final edited form as: Cancer Res. 2010 Oct 28;70(24):10038–10043. doi: 10.1158/0008-5472.CAN-10-2956

Figure 1. Tumor from crizotinib resistant patient contains a secondary ALK mutation.

Figure 1

A. Comparison of pre-treatment and post-treatment biopsy specimens. Both specimens contain viable tumor and both tumors express ALK by IHC which is localized to the nuclear membrane. FISH analyses demonstrate an ALK translocation (split red and green signals; arrows). Scale bar 50 μM. B. Sequence tracing from pre and post-treatment tumor specimens. There is a C to G mutation (asterix) in codon 3522 in exon 23 resulting in the F1174L mutation. This is not detected in the pre-treatment tumor.